Federated Hermes Inc. Buys 292,926 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Federated Hermes Inc. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 176.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 459,369 shares of the biopharmaceutical company’s stock after acquiring an additional 292,926 shares during the quarter. Federated Hermes Inc. owned about 0.35% of Halozyme Therapeutics worth $16,978,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Halozyme Therapeutics during the 4th quarter valued at about $196,000. EP Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $211,000. Pathstone Family Office LLC bought a new stake in shares of Halozyme Therapeutics during the third quarter valued at approximately $219,000. Tocqueville Asset Management L.P. purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $225,000. Finally, Gallacher Capital Management LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $235,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

HALO opened at $38.71 on Tuesday. Halozyme Therapeutics, Inc. has a 12-month low of $29.85 and a 12-month high of $45.00. The company has a market cap of $4.92 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 0.45 and a beta of 1.25. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The company’s 50 day moving average is $39.56 and its 200 day moving average is $37.77.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The business had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current year.

Analyst Ratings Changes

HALO has been the subject of a number of research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, April 17th. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. Benchmark reissued a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a report on Tuesday, December 26th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total value of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares of the company’s stock, valued at $6,473,094.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 30,000 shares of company stock worth $1,196,800 in the last three months. 2.70% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.